Keck School Faculty

Leslie Ballas, MD
Leslie Ballas, MD
Associate Professor of Clinical Radiation Oncology
Radiation Oncology
NOR G350 1441 EASTLAKE AVE Health Sciences Campus Los Angeles
Dr. Leslie Ballas is an Associate Professor of Clinical Radiation Oncology at USC Norris Cancer Hospital. She received her undergraduate degree from Cornell University, and her Medical Doctorate degree from the University of Michigan. She did her internship at Cornell in Surgery and her residency in Radiation Oncology at Cornell.

After residency, Dr. Ballas spent time on the faculty at MD Anderson Cancer Center treating hematologic malignancies (leukemia, lymphoma and multiple myeloma). She has considerable experience treating this patient population. Because many lymphomas are highly curable, management of long term side effects from treatment is essential. She uses a variety of treatment techniques and modalities to minimize radiation dose to normal structures, thereby minimizing late effects from treatment. She also has a great deal of experience working with cutaneous lymphomas and the management of this category of lymphomas.

Dr. Leslie Ballas also specializes in cancers of the genitourinary tract, including malignancies of the prostate, urinary bladder, testicle, and kidney. Her research has focused on improving quality of life for men with prostate cancer. She is involved in the development of cancer treatment clinical trials for patients with genitourinary cancers. And has brought multiple genitourinary cooperative group studies to USC. Dr. Ballas’ interests include advanced technology integration into cancer therapeutics, including image-guide radiation therapy (IGRT), stereotactic body radiotherapy (SBRT), and intensity modulated radiotherapy (IMRT).

Trimodality therapy for bladder cancer: modern management and future directions Curr Opin Urol. 2019 May; 29(3):210-215. . View in PubMed

Phase 1 Trial of SBRT to the Prostate Fossa After Prostatectomy Int J Radiat Oncol Biol Phys. 2019 May 01; 104(1):50-60. . View in PubMed

Trimodality therapy for bladder cancer: modern management and future directions Curr Opin Urol. 2019 Mar 06. . View in PubMed

18F-Fluciclovine PET/CT Detection of Recurrent Prostate Carcinoma in Patients With Serum PSA = 1 ng/mL After Definitive Primary Treatment Clin Nucl Med. 2019 Mar; 44(3):e128-e132. . View in PubMed

Adv Radiat Oncol. 2019 Jan-Mar; 4(1):96-102. . View in PubMed

Phase 1 Trial of SBRT to the Prostate Fossa After Prostatectomy Int J Radiat Oncol Biol Phys. 2018 Dec 31. . View in PubMed

18F-Fluciclovine PET/CT Detection of Recurrent Prostate Carcinoma in Patients With Serum PSA = 1 ng/mL After Definitive Primary Treatment Clin Nucl Med. 2018 Dec 26. . View in PubMed

National Practice Patterns and Overall Survival After Adjuvant Radiotherapy Following Radical Cystectomy for Urothelial Bladder Cancer in the USA, 2004-2013 Eur Urol Oncol. 2018 Dec 19. . View in PubMed

Risk factors for loco-regional recurrence after radical cystectomy of muscle-invasive bladder cancer: A systematic-review and framework for adjuvant radiotherapy Cancer Treat Rev. 2018 Nov; 70:88-97. . View in PubMed

Using hospital medical record data to assess the accuracy of the SEER Los Angeles Cancer Surveillance Program for initial treatment of prostate cancer: a small pilot study Cancer Causes Control. 2018 Sep; 29(9):815-821. . View in PubMed

Risk factors for loco-regional recurrence after radical cystectomy of muscle-invasive bladder cancer: A systematic-review and framework for adjuvant radiotherapy Cancer Treat Rev. 2018 Jul 21; 70:88-97. . View in PubMed

Using hospital medical record data to assess the accuracy of the SEER Los Angeles Cancer Surveillance Program for initial treatment of prostate cancer: a small pilot study Cancer Causes Control. 2018 Jul 18. . View in PubMed

Novel Treatment Setup for Urethral Cancer: Use of the Prone Technique for Radiotherapy of the Penis Case Rep Oncol. 2018 May-Aug; 11(2):268-275. . View in PubMed

Active Surveillance for Prostate Cancer: Are We Failing Latino Patients at a Large Safety Net Hospital? Clin Genitourin Cancer. 2018 Feb 06.. View in PubMed

PSMA PET: Transformational Change in Prostate Cancer Management? J Nucl Med. 2018 Feb; 59(2):228-229.. View in PubMed

Active Surveillance for Prostate Cancer: Are We Failing Latino Patients at a Large Safety Net Hospital? Clin Genitourin Cancer. 2018 08; 16(4):e719-e727.. View in PubMed

PSMA PET: Transformational Change in Prostate Cancer Management? J Nucl Med. 2018 02; 59(2):228-229.. View in PubMed

Tolerance of Orthotopic Ileal Neobladders to Radiotherapy: A Multi-institutional Retrospective Study Clin Genitourin Cancer. 2017 Dec; 15(6):711-716. . View in PubMed

Current Management Strategy for Penile Cancer and Future Directions Curr Oncol Rep. 2017 Aug; 19(8):54. . View in PubMed

Prostate-Specific Antigen and Prostate-Specific Antigen Kinetics in Predicting 18F-Sodium Fluoride Positron Emission Tomography-Computed Tomography Positivity for First Bone Metastases in Patients with Biochemical Recurrence after Radical Prostatectomy World J Nucl Med. 2017 Jul-Sep; 16(3):229-236. . View in PubMed

Immunotherapy in urothelial cancer, part 2: adjuvant, neoadjuvant, and adjunctive treatment Clin Adv Hematol Oncol. 2017 Jul; 15(7):543-551. . View in PubMed

Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease Clin Adv Hematol Oncol. 2017 Jun; 15(6):466-477. . View in PubMed

The Rationale for Post-Operative Radiation in Localized Bladder Cancer Bladder Cancer. 2017 Jan 27; 3(1):19-30. . View in PubMed

Tolerance of Orthotopic Ileal Neobladders to Radiotherapy: A Multi-institutional Retrospective Study Clin Genitourin Cancer. 2017 12; 15(6):711-716. . View in PubMed

What Medical, Urologic, and Radiation Oncologists Want from Molecular Imaging of Prostate Cancer J Nucl Med. 2016 Oct; 57(Suppl 3):6S-12S. . View in PubMed

Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy JAMA Oncol. 2016 Aug 01; 2(8):1065-9. . View in PubMed

ACR Appropriateness Criteria® Hodgkin Lymphoma-Favorable Prognosis Stage I and II Am J Clin Oncol. 2016 12; 39(6):535-544. . View in PubMed

ACR Appropriateness Criteria® Recurrent Hodgkin Lymphoma Oncology (Williston Park). 2016 12 15; 30(12):1099-103, 1106-8. . View in PubMed

Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis J Urol. 2015 Aug; 194(2):378-85. . View in PubMed

Modern radiotherapeutic strategies in the management of lymphoma Future Oncol. 2015; 11(6):1011-20. . View in PubMed

Chromoplexy and hypoxic microenvironment drives prostate cancer Lancet Oncol. 2014 Dec; 15(13):1419-21. . View in PubMed

Emergence of integrated urology-radiation oncology practices in the State of Texas Int J Radiat Oncol Biol Phys. 2012 Sep 01; 84(1):15-9. . View in PubMed

Cytogenetic profile of patients with acute myeloid leukemia and central nervous system disease Cancer. 2012 Jan 01; 118(1):112-7. . View in PubMed

Involved field radiation for Hodgkin's lymphoma: the actual dose to breasts in close proximity Med Dosim. 2012; 37(4):374-82. . View in PubMed

Treatment interruption and discontinuation in radiotherapy for rectal cancer Cancer Invest. 2010 Mar; 28(3):289-94. . View in PubMed

Advances in radiobiological studies using a microbeam J Radiat Res. 2009 Mar; 50 Suppl A:A7-A12. . View in PubMed

Radiation therapy facilities in the United States Int J Radiat Oncol Biol Phys. 2006 Nov 15; 66(4):1204-11. . View in PubMed

Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor Science. 1996 May 03; 272(5262):728-31. . View in PubMed

Powered by SC CTSI
Go to Top